NO20082145L - Prolinamidderivater som natriumkanalmodulatorer - Google Patents

Prolinamidderivater som natriumkanalmodulatorer

Info

Publication number
NO20082145L
NO20082145L NO20082145A NO20082145A NO20082145L NO 20082145 L NO20082145 L NO 20082145L NO 20082145 A NO20082145 A NO 20082145A NO 20082145 A NO20082145 A NO 20082145A NO 20082145 L NO20082145 L NO 20082145L
Authority
NO
Norway
Prior art keywords
sodium channel
channel modulators
prolinamide derivatives
prolinamide
derivatives
Prior art date
Application number
NO20082145A
Other languages
English (en)
Norwegian (no)
Inventor
Giuseppe Alvaro
Markus Bergauer
Riccardo Giovannini
Roberto Profeta
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0520581A external-priority patent/GB0520581D0/en
Priority claimed from GB0523045A external-priority patent/GB0523045D0/en
Priority claimed from GB0603900A external-priority patent/GB0603900D0/en
Priority claimed from GB0618336A external-priority patent/GB0618336D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20082145L publication Critical patent/NO20082145L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO20082145A 2005-10-10 2008-05-07 Prolinamidderivater som natriumkanalmodulatorer NO20082145L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0520581A GB0520581D0 (en) 2005-10-10 2005-10-10 Novel compounds
GB0523045A GB0523045D0 (en) 2005-11-11 2005-11-11 Novel compounds
GB0603900A GB0603900D0 (en) 2006-02-27 2006-02-27 Novel compounds
GB0618336A GB0618336D0 (en) 2006-09-18 2006-09-18 Novel compounds
PCT/EP2006/009731 WO2007042239A1 (en) 2005-10-10 2006-10-06 Prolinamide derivatives as sodium channel modulators

Publications (1)

Publication Number Publication Date
NO20082145L true NO20082145L (no) 2008-05-07

Family

ID=37546777

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082145A NO20082145L (no) 2005-10-10 2008-05-07 Prolinamidderivater som natriumkanalmodulatorer

Country Status (20)

Country Link
US (2) US7655693B2 (enExample)
EP (1) EP1934177B8 (enExample)
JP (1) JP5139305B2 (enExample)
KR (1) KR101282464B1 (enExample)
AR (1) AR056575A1 (enExample)
AT (1) ATE556049T1 (enExample)
AU (1) AU2006301470B2 (enExample)
BR (1) BRPI0616944B8 (enExample)
CA (1) CA2625642C (enExample)
CR (1) CR9898A (enExample)
EA (1) EA015736B1 (enExample)
ES (1) ES2387405T3 (enExample)
IL (1) IL192627A0 (enExample)
MA (1) MA29817B1 (enExample)
NO (1) NO20082145L (enExample)
NZ (1) NZ567051A (enExample)
PE (1) PE20070592A1 (enExample)
PL (1) PL1934177T3 (enExample)
TW (1) TW200730494A (enExample)
WO (1) WO2007042239A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143306B2 (en) * 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
US7855218B2 (en) * 2005-10-10 2010-12-21 Convergence Pharmaceuticals Limited Compounds
GB0701365D0 (en) * 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
WO2011015537A1 (en) 2009-08-05 2011-02-10 Glaxo Group Limited Co-therapy for the treatment of epilepsy and related disorders
HRP20150491T1 (hr) 2009-09-14 2015-08-14 Convergence Pharmaceuticals Limited PROCES PRIPREME DERIVATA α-KARBOKSAMIDA
ES2786298T3 (es) 2011-03-03 2020-10-09 Zalicus Pharmaceuticals Ltd Inhibidores de benzimidazol del canal de sodio
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
CN106255679B (zh) 2014-02-27 2019-09-06 默克专利有限公司 用作nav通道抑制剂的杂环化合物及其用途
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
CA3042384A1 (en) * 2016-11-02 2018-05-11 Biogen Ma Inc. Novel dosage regimen
CA3062884A1 (en) * 2017-05-19 2018-11-22 Biogen Ma Inc. Novel crystalline forms
EP3691634A4 (en) * 2017-10-05 2021-03-31 Biogen Inc. PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES
CA3077088A1 (en) 2017-10-10 2019-04-18 Biogen Inc. Process for preparing spiro derivatives
AU2019255519A1 (en) * 2018-04-16 2020-10-01 Biogen Ma Inc. Methods of treating neuropathic pain
MX2021012421A (es) * 2019-04-10 2022-02-10 Biogen Inc Procesos para preparar derivados de pirrolidina alfa-carboxamida.
EA202192762A1 (ru) * 2019-04-10 2022-03-21 Байоджен Ма Инк. Способ получения производных альфа-карбоксамид пирролидина
EP4096508A4 (en) 2020-01-30 2024-03-27 Javed, Mohammad COMBINATION MEDICINAL THERAPIES FOR CNS DISEASES

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
US6136131A (en) * 1998-06-02 2000-10-24 Instrument Specialties Company, Inc. Method of shielding and obtaining access to a component on a printed circuit board
RU2001129155A (ru) 1999-03-26 2003-08-10 Еро-Сельтик С.А. (Lu) Соединения с арильными заместителями (варианты), фармацевтическая композиция и способ лечения расстройства, чувствительного к блокаде натриевых каналов у млекопитающего, способ лечения, профилактики различных заболеваний или уменьшения интенсивности гибели или потери нейронов (варианты), способ облегчения или предупреждения эпилептических припадков у животного (варианты), соединение - радиоактивный лиганд для участка связывания в натриевом канале
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0115517D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
MY134480A (en) * 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
CN101333192A (zh) 2003-04-03 2008-12-31 默克公司 作为钠通道阻滞剂的联芳基取代吡唑
JP2006523701A (ja) 2003-04-18 2006-10-19 メルク エンド カムパニー インコーポレーテッド ナトリウムチャネルブロッカーとしてのビアリール置換チアゾール、オキサゾール、およびイミダゾール
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1524265A1 (en) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors
WO2005100334A1 (en) * 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
WO2006119451A1 (en) 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyrimidines and pyrazines useful as modulators of ion channels
JP2008540438A (ja) 2005-05-04 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なピリジン
JP2008540665A (ja) 2005-05-19 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なビアリール
PT1928886E (pt) * 2005-09-09 2011-07-14 Glaxosmithkline Llc Derivados de piridina e sua utilização para o tratamento de distúrbios psicóticos
US7855218B2 (en) 2005-10-10 2010-12-21 Convergence Pharmaceuticals Limited Compounds
TW200728258A (en) * 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
JP2009511519A (ja) 2009-03-19
EP1934177A1 (en) 2008-06-25
ES2387405T3 (es) 2012-09-21
CA2625642A1 (en) 2007-04-19
JP5139305B2 (ja) 2013-02-06
PE20070592A1 (es) 2007-06-23
KR101282464B1 (ko) 2013-07-04
PL1934177T3 (pl) 2013-03-29
AU2006301470B2 (en) 2012-06-14
NZ567051A (en) 2011-03-31
MA29817B1 (fr) 2008-09-01
TW200730494A (en) 2007-08-16
AU2006301470A1 (en) 2007-04-19
AR056575A1 (es) 2007-10-10
CR9898A (es) 2008-07-29
US8153681B2 (en) 2012-04-10
BRPI0616944B1 (pt) 2020-04-14
BRPI0616944A2 (pt) 2011-07-05
EA200801054A1 (ru) 2008-08-29
US7655693B2 (en) 2010-02-02
US20080280969A1 (en) 2008-11-13
IL192627A0 (en) 2011-08-01
ATE556049T1 (de) 2012-05-15
BRPI0616944B8 (pt) 2021-05-25
WO2007042239A1 (en) 2007-04-19
EP1934177B1 (en) 2012-05-02
US20100105754A1 (en) 2010-04-29
CA2625642C (en) 2013-12-24
KR20080059296A (ko) 2008-06-26
EP1934177B8 (en) 2012-09-05
EA015736B1 (ru) 2011-10-31

Similar Documents

Publication Publication Date Title
NO20082145L (no) Prolinamidderivater som natriumkanalmodulatorer
NO20070855L (no) Arylidener for behandling av estrogenrelaterte reseptor-alfamedierte sykdommer.
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
NO20081788L (no) Cyklopropylaminer som modulatorer av histamin-H3-reseptoren
MX2009002002A (es) Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
MX2007007845A (es) Sulfonilpirrolidinas, metodo para producir las mismas y su uso como medicamento.
EA201001848A1 (ru) Производные пиразина в качестве блокаторов эпителиальных натриевых каналов
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
EA201000886A1 (ru) Органические соединения
NO20076306L (no) Bicykliske derivater som modulatorer av ionekanaler
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
EA200600203A1 (ru) Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
NO20060688L (no) Fusjonerte aryl- og heteroarylderivater som modulatorer av metabolisme og profylakse og behandling av lidelser relatert til dette
NO20073926L (no) Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
EP1605752A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
CY1112921T1 (el) Ενεργοποιητες γλυκοκινασης πυρρολιδινονης
NO20076254L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
NO20076137L (no) Nye 2-azetidinonderivater og deres anvendelse som kolestrolabsorpsjonsinhibitorer for behandling av hyperlipidemi
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
WO2007067711A3 (en) Certain chemical entities, compositions, and methods for modulating trpv1
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
WO2007052123A3 (en) Pyrazine derivatives as sodium channel modulators for the treatment of pain

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application